JOSEPH JAMES DUDEK M.D. NPI 1417929282

NPI Information

  • NPI: 1417929282
  • Provider Name: JOSEPH JAMES DUDEK, M.D.
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 400 PATROON CREEK BLVD
    SUITE 1
    ALBANY, NY
    ZIP 12206
  • Phone: (518) 489-0044

Map and Directions

Get Directions

NPI Details

Joseph James Dudek, M.D. is a hematology and oncology internal medicine in Albany, NY with 43 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Joseph James Dudek, M.D. NPI is 1417929282. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: ST. LOUIS COLLEGE OF PHYSICIANS AND SURGEONS
Graduation Year:1983

The provider's business location address is:

400 PATROON CREEK BLVD
SUITE 1
ALBANY, NY
ZIP 12206-004
Phone: (518) 489-0044
Fax: (518) 489-3591

The NPI 1417929282 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
  • Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
  • Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
  • Gammaglobulin (immune system protein) measurement (HCPCS:82784)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Measurement of substance using immunoassay technique (HCPCS:83520)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection, irinotecan, 20 mg (HCPCS:J9206)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Iron level (HCPCS:83540)
  • Iron binding capacity (HCPCS:83550)
  • Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
  • Blood test, clotting time (HCPCS:85610)
  • Vitamin d-3 level (HCPCS:82306)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
  • Magnesium level (HCPCS:83735)
  • Thyroxine (thyroid chemical), free (HCPCS:84439)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • Psa (prostate specific antigen) measurement, total (HCPCS:84153)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Ct scan of chest with contrast (HCPCS:71260)
  • Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
  • Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Unclassified drugs (HCPCS:J3490)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
  • Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Red blood count automated, with additional calculations (HCPCS:85046)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
  • Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
  • Ct scan of chest without contrast (HCPCS:71250)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Nuclear medicine study whole body with ct scan (HCPCS:78816)
  • Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
  • Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Uric acid level, blood (HCPCS:84550)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
  • Beta-2 microglobulin (protein) level (HCPCS:82232)

The enumeration date for this NPI number is 2/6/2006 and was last updated on 3/19/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & Oncology182271NEW YORKYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.